Journal of cosmetic dermatology · 2026
A Multicenter Trial of an Enhanced Serum Comprised of 13 Plant-Based Adaptogens Targeting Skin Quality in Females Impacted by Hormonal Decline.
СтатьяМногоцентровое исследованиеКлиническое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Draelos Zoe D, Moradi Amir, Smathers Amber
Аннотация
OBJECTIVES: To assess the effectiveness and tolerability of a serum comprised of plant-based adaptogens (MYS-REV) for visible improvements in skin changes caused by hormonal fluctuations associated with perimenopause and postmenopause in women.
STUDY DESIGNS: A 16-week open-label multicenter study evaluated the efficacy and tolerability of twice-daily application of MYS-REV in females, aged ≥ 46 years, Fitzpatrick skin type (FST) I-VI, with fine-to-moderate depth lines and wrinkles, mild-to-moderate elastosis, and crepey skin. Investigators assessed improvements in depth and number of lines/wrinkles, elastosis, and crepey skin. Additionally, investigators assessed improvements in appearance of skin dullness, skin roughness/texture, erythema, uneven pigmentation, and pore size, along with objective changes in skin hydration and transepidermal water loss (TEWL), all over 16 weeks. Tolerability and subject self-assessment were assessed over 16 weeks.
RESULTS: At 16 weeks, twice-daily use of MYS-REV demonstrated mean percent improvements in elastosis/crepey skin, lines/wrinkles, skin hydration, and TEWL, and in erythema, dullness, texture/roughness, pore size, and uneven pigmentation (all p < 0.0001). All AEs were mild with no study discontinuations owing to any AE. Subjects reported high levels of satisfaction with MYS-REV beginning as early as 4 weeks and continuing through Week 16.
CONCLUSIONS: This study demonstrated that twice-daily application of MYS-REV visibly improves skin affected by menopause-related hormonal fluctuations.
STUDY DESIGNS: A 16-week open-label multicenter study evaluated the efficacy and tolerability of twice-daily application of MYS-REV in females, aged ≥ 46 years, Fitzpatrick skin type (FST) I-VI, with fine-to-moderate depth lines and wrinkles, mild-to-moderate elastosis, and crepey skin. Investigators assessed improvements in depth and number of lines/wrinkles, elastosis, and crepey skin. Additionally, investigators assessed improvements in appearance of skin dullness, skin roughness/texture, erythema, uneven pigmentation, and pore size, along with objective changes in skin hydration and transepidermal water loss (TEWL), all over 16 weeks. Tolerability and subject self-assessment were assessed over 16 weeks.
RESULTS: At 16 weeks, twice-daily use of MYS-REV demonstrated mean percent improvements in elastosis/crepey skin, lines/wrinkles, skin hydration, and TEWL, and in erythema, dullness, texture/roughness, pore size, and uneven pigmentation (all p < 0.0001). All AEs were mild with no study discontinuations owing to any AE. Subjects reported high levels of satisfaction with MYS-REV beginning as early as 4 weeks and continuing through Week 16.
CONCLUSIONS: This study demonstrated that twice-daily application of MYS-REV visibly improves skin affected by menopause-related hormonal fluctuations.